PTPI
Petros Pharmaceuticals, Inc.
Next earnings ≈ Aug 12, 2026 · est. from filing cadence
$0.01
▼ -13.79%$0.01▼ -85.29%
over 1Y
L $0.01H $0.04
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-13.8%
1W-16.7%
1M-16.7%
3M+0.0%
YTD-37.5%
1Y-85.3%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Strong net margin (37.4%); but revenue fell -12.2% YoY.
Revenue (FY2024) $5.11M · FY2024
Petros Pharmaceuticals, Inc. shows $5.11M in FY2024 revenue (-12.2% YoY), a 37.4% net margin, and 66.7% ROE.
Supporting the case: strong net margin (37.4%); high return on equity (66.7%); conservative balance sheet (liabilities/equity 0.80x).
Is PTPI a buy? The one-page verdict, explained →
The options angle
model · matches our verdictCovered call~60d expiry
- Long 100 shares @ ~0.01
- Short call 0 @ ~0.00 est
debit $1max +−$1max −$1
HOLD means own it, don't chase it — harvesting premium against the position matches the verdict.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $7.81M | $5.99M | $5.82M | $5.11M | — |
| Gross profit | $6.21M | $3.70M | $4.19M | $3.90M | — |
| Operating income | -$18.0M | -$19.9M | -$13.6M | -$4.63M | -$4.64M |
| Net income | -$8.99M | -$20.0M | -$8.16M | -$14.3M | $1.91M |
| Diluted EPS | -$8.25 | -$9.68 | -$6.35 | -$83.47 | -$1.56 |
| Net margin | -115.0% | -334.4% | -140.2% | -280.1% | — |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$2.25M
EV / EBITDA—
EV / Sales0.4
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield903.2%
FCF yield-3190.4%
Quality & risk
ROIC (est.)-36.5%
Free cash flow-$6.76M
Total debt$7.18M
Net cash-$2.04M
Altman Z-Score-31.43 distress
Piotroski F-Score6/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-20.8%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — late filing notice (2026-03-31). Worth a closer look.
- 8-K Officer / director change2026-06-18
- 8-K Officer / director change2026-06-05
- 10-Q Quarterly report2026-05-13
- 10-K Annual report2026-04-15
- NT 10-K Late filing notice2026-03-31
- 8-K Officer / director change2026-01-02
- 10-Q Quarterly report2025-11-13
- 8-K Delisting notice2025-11-07
- 8-K Auditor change2025-09-05
Recent filings
all on EDGAR ↗3Period ending 2026-06-182026-06-25open ↗8-KPeriod ending 2026-06-182026-06-18open ↗4Period ending 2026-06-052026-06-08open ↗4Period ending 2026-06-052026-06-05open ↗4Period ending 2026-06-052026-06-05open ↗4Period ending 2026-06-052026-06-05open ↗8-KPeriod ending 2026-06-052026-06-05open ↗10-QPeriod ending 2026-03-312026-05-13open ↗10-KPeriod ending 2025-12-312026-04-15open ↗NT 10-KPeriod ending 2025-12-312026-03-31open ↗SCHEDULE 13G/AFiling2026-02-17open ↗4Period ending 2026-01-022026-01-06open ↗
Frequently asked
- Is Petros Pharmaceuticals, Inc. (PTPI) a buy?
- PTPI currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Strong net margin (37.4%); but revenue fell -12.2% YoY.
- What is Petros Pharmaceuticals, Inc.'s quality score?
- PTPI scores 63.96436781609194/100 (grade C+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001815903, latest 10-Q filed 2026-05-13) · EODHD · as of 6/22/2026, 10:54:37 PM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 22, 2026, 6:54 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.